Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its ...

Amgen’s fourth-quarter results reflected broad-based sales growth across its diverse portfolio, with management crediting strong volume gains in key products such as Repatha, Evenity, and Tezspire.

The global obesity drugs market is projected to grow at a robust compound annual growth rate (CAGR) of approximately 25% ...

US biotech giant Amgen today announced the European Commission (EC) has approved Uplizna (inebilizumab) as an add-on ...

Hyderabad: Telangana is all set to stake claim to pole position as a global techbio hub with BioAsia 2026, which kicks off on Tuesday with a speaker l.

Amgen (NASDAQ:AMGN) today announced the European Commission (EC) has approved UPLIZNA® (inebilizumab) as an add-on treatment to ...

InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming ...

Preemptive cyber defense team releases list of 100+ high-value targets We expect the targeting list to evolve rapidly ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...

Swiss biotech in particular saw strong activity in 2025 with the establishment of 15 new life sciences companies. In January, several Swiss life sciences start-ups announced significant financings and ...

Explore the 19th Asian Financial Forum 2026 highlights, featuring insights on AI and Hong Kong’s role in cross-border ...